Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity
AbstractHuntington’s disease (HD) is an autosomal dominant neurodegenerative disease caused by the expansion of a CAG trinucleotide repeat encoding an abnormally long polyglutamine tract (PolyQ) in the huntingtin (Htt) protein. In HD, striking neuropathological changes occur in the striatum, including loss of medium spiny neurons and parvalbumin-expressing interneurons accompanied by neurodegeneration of the striosome and matrix compartments, leading to progressive impairment of reasoning, walking and speaking abilities. The precise cause of striatal pathology in HD is still unknown; however, accumulating clinical and experimental evidence suggests multiple plausible pathophysiological mechanisms underlying striatal neurodegeneration in HD. Here, we review and discuss the characteristic neurodegenerative patterns observed in the striatum of HD patients and consider the role of various huntingtin-related and striatum-enriched proteins in neurotoxicity and neuroprotection. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Morigaki, R.; Goto, S. Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity. Brain Sci. 2017, 7, 63.
Morigaki R, Goto S. Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity. Brain Sciences. 2017; 7(6):63.Chicago/Turabian Style
Morigaki, Ryoma; Goto, Satoshi. 2017. "Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity." Brain Sci. 7, no. 6: 63.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.